- Home
- PASG vs CLDI Comparison
PASG vs CLDI Comparison
Compare PASG & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PASG
- CLDI
- Stock Information
- Founded
- PASG 2017
- CLDI 2014
- Country
- PASG United States
- CLDI United States
- Employees
- PASG N/A
- CLDI N/A
- Industry
- PASG Biotechnology: Pharmaceutical Preparations
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PASG Health Care
- CLDI Health Care
- Exchange
- PASG Nasdaq
- CLDI Nasdaq
- Market Cap
- PASG 20.3M
- CLDI 20.2M
- IPO Year
- PASG 2020
- CLDI N/A
- Fundamental
- Price
- PASG $6.95
- CLDI $5.30
- Analyst Decision
- PASG Strong Buy
- CLDI
- Analyst Count
- PASG 4
- CLDI 0
- Target Price
- PASG $59.25
- CLDI N/A
- AVG Volume (30 Days)
- PASG 82.4K
- CLDI 961.3K
- Earning Date
- PASG 08-12-2025
- CLDI 08-08-2025
- Dividend Yield
- PASG N/A
- CLDI N/A
- EPS Growth
- PASG N/A
- CLDI N/A
- EPS
- PASG N/A
- CLDI N/A
- Revenue
- PASG N/A
- CLDI N/A
- Revenue This Year
- PASG N/A
- CLDI N/A
- Revenue Next Year
- PASG N/A
- CLDI N/A
- P/E Ratio
- PASG N/A
- CLDI N/A
- Revenue Growth
- PASG N/A
- CLDI N/A
- 52 Week Low
- PASG $5.12
- CLDI $2.43
- 52 Week High
- PASG $26.60
- CLDI $46.68
- Technical
- Relative Strength Index (RSI)
- PASG 53.66
- CLDI 44.17
- Support Level
- PASG $5.51
- CLDI $4.85
- Resistance Level
- PASG $6.27
- CLDI $6.06
- Average True Range (ATR)
- PASG 0.66
- CLDI 1.03
- MACD
- PASG 0.19
- CLDI -0.31
- Stochastic Oscillator
- PASG 68.76
- CLDI 8.91
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.